Hyperfine, Inc.
NASDAQ:HYPRMedical - Devices
+$0.22 today
- Market cap
- $51.10M
- Beta
- 1.38
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.36
Volume 1.16M
Average 0.60M
HYPR Sales of Investments
Cash received from selling or redeeming investments.
Hyperfine, Inc.NASDAQ: HYPR
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments outflow grows to $0
Q1 FY2026 sales of investments was $0, compared with $0 a year earlier. Trailing-twelve-month sales of investments was $0.
Context
- Sales of investments amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Sales of investments increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly sales of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Sales of Investments vs competitors
How HYPR compares with its peers on the latest reported figures
- HYPR's LTM Mar 2026 sales of investments of $0 is the 6th largest of the 7 companies compared; the peer median is $8.03M.
- Sales of investments amounts to 0.0% of revenue for HYPR, versus a peer median of 24.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | $39.95M | +216.4% | +5.0% | 62417.2% | |
| LTM Mar 2026 | $22.5M | -64.3% | -20.9% | 31.1% | |
| LTM Mar 2026 | $16.05M | -71.1% | -6.2% | 18.1% | |
IMAImageneBio Inc | LTM Mar 2026 | $4.82M | -106.7% | -56.4% | — |
| LTM Mar 2026 | $2.61K | -79.9% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding HYPR) | $8.03M | -71.1% | -13.5% | 24.6% | |
Competitors are the stored peer set for HYPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (64.85M) | (73.16M) | (44.24M) | (40.72M) | (35.57M) |
| Depreciation & Amortization | 726K | 1.02M | 1.05M | 1.01M | 1.09M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.9M | 10.65M | 4.74M | 4.36M | 2.8M |
| Change in Working Capital | 8.97M | (10.93M) | (3.62M) | (3.62M) | 4.41M |
| Accounts Receivables | 981K | (1.55M) | (1.57M) | (2.77M) | 1.78M |
| Inventory | (2.67M) | (312K) | (2.21M) | 562K | (1.48M) |
| Accounts Payables | 1.44M | (1.57M) | 533K | 382K | 2.43M |
| Other Working Capital | 9.22M | (7.5M) | (365K) | (1.8M) | 1.68M |
| Other Non-Cash Items | 1.07M | 91K | 249K | 204K | (677K) |
| Operating Cash Flow | (47.18M) | (72.34M) | (41.81M) | (38.77M) | (27.95M) |
| Capital Expenditures | (2.71M) | (585K) | (804K) | (383K) | (1.19M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (2.71M) | (585K) | (804K) | (383K) | (1.19M) |
| Debt Repayment | (178K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.5M | 7K | 174K | 848K | 27.5M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 146.48M | 0 | 0 | 171K | 0 |
| Financing Cash Flow | 176.77M | 7K | 174K | 1.02M | 27.5M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 126.87M | (72.92M) | (42.44M) | (38.13M) | (1.63M) |
| Free Cash Flow | (49.89M) | (72.92M) | (42.61M) | (39.15M) | (29.13M) |
Hyperfine, Inc.
NASDAQ:HYPR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.